Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 68, Issue 10, 2009, Pages 1654-

  De Kruif, M D ^a,b   Limper, M ^a,b   Hansen, H R ^a,b   De Ruiter, J ^a   Spek, C A ^b   Van Gorp, E C M ^a   Ten Berge, I J ^b   Rowshani, A T ^b   Ten Cate, H ^c   Meesters, E W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LETTER; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

C-REACTIVE PROTEIN; CROSS-OVER STUDIES; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PYRIMIDINES; SULFONAMIDES;

EID: 70349400510     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.109405     Document Type: Letter

References (10)

1. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-2021 (Pubitemid 38781100)
2. Corzillius M, Bae SC. Methodological issues of corticosteroid use in SLE clinical trials. Lupus 1999;8:692-697 (Pubitemid 29520537)
3. Tikiz C, Utuk O, Pirildar T, et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005;32:2095-2101 (Pubitemid 41587851)
4. Kanda H, Yokota K, Kohno C, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol 2007;17:364-368 (Pubitemid 47593482)
5. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterollowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-2009 (Pubitemid 46734641)
6. Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007;27:1071-1077 (Pubitemid 47246586)
7. Knapp AC, Huang J, Starling G, et al. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000;152:217-227
8. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-1402 (Pubitemid 32001026)
9. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84. (Pubitemid 35291443)
10. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-611 (Pubitemid 37021796)